CN102600342A - Specific medicine for treating coronary disease - Google Patents
Specific medicine for treating coronary disease Download PDFInfo
- Publication number
- CN102600342A CN102600342A CN2012100962996A CN201210096299A CN102600342A CN 102600342 A CN102600342 A CN 102600342A CN 2012100962996 A CN2012100962996 A CN 2012100962996A CN 201210096299 A CN201210096299 A CN 201210096299A CN 102600342 A CN102600342 A CN 102600342A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- heart disease
- coronary heart
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of medicaments, in particular to a specific medicine for treating coronary disease. The specific medicine for treating coronary disease comprises the following components by weight: 1.8-2.2 parts of Chinese caterpillar fungus, 1.3-1.7 parts of Crocus sativus flower, 7.8-8.3 parts of Scorpio, 5.8-6.2 parts of Panax notoginseng, 8.8-9.2 parts of tortoise plastron, 9.8-10.2 parts of Colla Asini, 29.8-30.3 parts of jujube seed, 9.7-10.2 parts of Angelica sinensis, 11.7-12.3 parts of Bulbus Allii Macrostemonis (Allium macrostemon and/or Allium chinensis), 2.8-3.3 parts of Herba Asari, 11.8-12.3 parts of mint, 9.8-10.3 parts of lotus flower, 9.8-10.3 parts of pagodatree pod, 9.8-10.3 parts of Vascular Aurantii, and 23.8-24.3 parts of Cynomorium songaricum. The preparation improves human immunologic mechanism and strengthens human resistibility by conditioning Qi and blood, promoting circulation, removing stasis, and nourishing the liver and the kidney, thereby implementing the functions of dilating blood vessels, repairing vascular walls, and enhancing cardiac power. The preparation can really promote cardiac rehabilitation and physical health for patients with coronary disease.
Description
Technical field
The present invention relates to field of medicaments, be specifically related to a kind of specific drug of treating coronary heart disease.
Background technology
As the big killer's in third place in the world coronary heart disease (coronary atherosclerotic heart disease), be a kind of modal heart disease, be meant the myocardial dysfunction that causes because of coronary stricture, blood supply insufficiency and (or) organic disease, so claim ischemic cardiomyopathy again.Coronary heart disease is the result of multiple coronary artery disease, but coronary atherosclerosis accounts for overwhelming majority's (95%～99%) of coronary heart disease.According to its clinical shape disease, coronary heart disease mainly is divided into angina pectoris, myocardial infarction, silent myocardial ischemia, heart failure and arrhythmia type, sudden death type five big typings.The primary disease cause of disease is unclear fully as yet so far, but thinks that lowly to reach factor such as older relevant with hypertension, hyperlipemia, high blood viscosity, smoking, obesity, endocrine function, heredity is still also arranged, drinks, factor such as environment.
Becoming younger of patients with coronary heart disease spread in recent years, has to cause our attention and watch out for that only just there is nearly ten million middle-aged and elderly people the Shandong Province, yet accounts for unexpectedly more than 50% at the sickness rate of nearly population center's disease of ZANG-organs of ten million, attaches most importance to coronary heart disease especially.Improving constantly of Along with people's living standard, everybody more and more payes attention to health care, and the cardiovascular disease that influences middle-aged and elderly people is also more and more outstanding, and " be the health decompression, be the heart Reduction of Students' Study Load " is very urgent.
" Radix Salviae Miltiorrhizae Tabellae " has good effect on treatment coronary heart disease, cerebral infarction are waited indefinitely disease; It is a kind of Chinese patent medicine commonly used clinically; It extracts after by the single Radix Salviae Miltiorrhizae extractum and forms, and its main acting body is present: heart tonifying, coronary artery dilating, increase myocardial flow; Expansion peripheral blood vessel, blood flow increase; Cerebral blood flow descends; Antithrombotic forms, improves plasmin activity; Prolong, clotting time; Anticoagulant (it is synthetic to improve the interior cAMP level inhibition of platelet TXA2); Improve hemorheological properties (blood viscosity reduction, erythrocyte electrophoretic time shorten); Aspects such as microcirculation improvement.Except that above-mentioned effect, Radix Salviae Miltiorrhizae also has various effects such as antitumor, human body immunity improving power, the liver protecting, the relieving restlessness that clears away heart-fire.But FUFANG DANSHEN PIAN is taken in a short time and possibly is free from side effects, if but take FUFANG DANSHEN PIAN for a long time and possibly cause hypokalemia.Find that after deliberation the patients with coronary heart disease that has was taken FUFANG DANSHEN PIAN 1 month continuously by convention amount, the blood potassium level reduces before the treatment, and abdominal distention, potassium deficiency performance such as weak can appear in patient.Research thinks that the compound Salviae Miltiorrhizae sector-meeting causes hypokalemia, maybe be relevant to the influence of renal function with the principal agent Radix Salviae Miltiorrhizae.Pharmacological research proves that Radix Salviae Miltiorrhizae can obviously improve renal function, and glomerular filtration rate (GFR), RPF (RDF), renal blood flow (RBF) are significantly increased, and flow velocity is accelerated.According to research; When the increase of distal renal tubular flow quantity, when flow velocity is accelerated; Can effective stimulus renal tubules cortex secrete potassium ion, and the potassium major part of discharging in the urine is that distal renal tubular and collecting tubule are secreted, i.e. kaliuresis amount depends primarily on the speed of distal nephron secretion potassium.Therefore, take Radix Salviae Miltiorrhizae for a long time and might cause kaliuresis, make blood potassium reduce, and myasthenia can appear in low patient's initial stage of blood potassium, the severe patient tendon reflex disappears or collapses from physical exhaustion.Later stage can cause heart beating slack-off, atrium dysrhythmia ventricular premature contraction, and pulse is thin and delicate, arrhythmia, severe patient threat to life.
" WENXIN KELI " also is supplementing QI and nourishing YIN, the multiple arteries and veins of throbbing with fear surely, blood circulation promoting and blood stasis dispelling.Cure mainly the deficiency of both QI and YIN palpitation and uneasiness due to the heart arteries and veins stasis of blood resistance of holding concurrently, shortness of breath and fatigue, dizzy vexed, the medicine a kind of commonly used of feeling of oppression and pain in the chest.Be applicable to arrhythmia such as premature beat that a variety of causes causes, atrial fibrillation, sinus tachycardia.Radix Codonopsis, Rhizoma Polygonati, Radix Notoginseng, succinum, Radix Et Rhizoma Nardostachyos.Accidental Blushing, gastrointestinal reaction, xerostomia, agitation, slight dizzy, the symptom of feeling sick.
In sum, the medicine of the coronary heart disease of China's treatment is at present just alleviated mostly and is stablized the state of an illness, takes stopgap measures and does not effect a permanent cure, and need take for a long time, and some medicine also has side effect, and is unfavorable to patient body.
Summary of the invention
In order to address the above problem, the object of the present invention is to provide a kind of specific drug that can really make the treatment coronary heart disease of coronary heart disease heart of patient rehabilitation.
For realizing the foregoing invention purpose, technical scheme that the present invention adopts is following:
A kind of specific drug of treating coronary heart disease comprises the component of following weight portion:
1.8～2.2 parts of Cordyceps, 1.3～1.7 parts of Stigma Crocis, 7.8～8.3 parts of Scorpio, 5.8～6.2 parts of Radix Notoginseng, 8.8～9.2 parts of Carapax et Plastrum Testudiniss, 9.8～10.2 parts in Colla Corii Asini, 29.8～30.3 parts of Semen Ziziphi Spinosaes, 9.7～10.2 parts of Radix Angelicae Sinensis, 11.7～12.3 parts of Bulbus Allii Macrostemonis, 2.8～3.3 parts of Herba Asaris, 11.8～12.3 parts of Herba Menthaes, 9.8～10.3 parts of Flos Nelumbinises, 9.8～10.3 parts of the Fructuss Sophorae, 9.8～10.3 parts of vascular aurantii, 23.8～24.3 parts of Herba Cynomoriis.
Preferably, a kind of specific drug of treating coronary heart disease also can comprise the component of following weight portion:
2 parts of Cordyceps, 1.5 parts of Stigma Crocis, 8 parts of Scorpio, 6 parts of Radix Notoginseng, 9 parts of Carapax et Plastrum Testudiniss, 10 parts in Colla Corii Asini, 30 parts of Semen Ziziphi Spinosaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Bulbus Allii Macrostemonis, 3 parts of Herba Asaris, 12 parts of Herba Menthaes, 10 parts of Flos Nelumbinises, 10 parts of the Fructuss Sophorae, 10 parts of vascular aurantii, 24 parts of Herba Cynomoriis.、
Preferably, the specific drug its preparation method of treatment coronary heart disease is above-mentioned medicaments in part by weight to be mixed pulverize, and quantitatively incapsulates to get final product.
The present invention has following beneficial effect:
(1) monarch drug is a Cordyceps in the said preparation, can protect lung kidney tonifying, the logical heart arteries and veins of a surname, relieving cough and resolving phlegm; Ministerial drug is Carapax et Plastrum Testudinis, Colla Corii Asini, Semen Ziziphi Spinosae, but the fire of nourishing YIN for suppressing the hyperactive YANG, moisturizing, tranquilizing by nourishing the heart; Adjuvant drug is Radix Angelicae Sinensis, Radix Notoginseng, Stigma Croci, but nourshing blood and promoting blood circulation blood stasis dispelling, blood vessel dilating, improves blood circulation; Messenger drug is Bulbus Allii Macrostemonis, Herba Asari, but activating stagnated YANG; Herba Menthae can be regulated the flow of vital energy; But Flos Nelumbinis the lucid yang sending up; But Fructus Sophorae removing heat from blood.The monarch medicine complements each other; Adopt the theory of equilibrium between yin and yang, mutual generation of five phases restriction or checking relation in five elements and the integral body sight of the traditional Chinese medical science, dialectical sight; Improve human immunity mechanism through the two accent of QI and blood, blood circulation promoting and blood stasis dispelling, nourishing liver and kidney; The enhances human body resistance, thus reach blood vessel dilating, repair blood vessel wall, increase the effect of heart power, thus really make coronary heart disease heart of patient rehabilitation, healthy.Through clinical verification, after patient used three courses of treatment, cardiac rehabilitation was obvious, and no uncomfortable symptom after the drug withdrawal.
(2) treat the medicine of coronary heart disease on the market now; Usually need the patient to take the development that medicine is controlled coronary heart disease for a long time, and the appearance of " going back heart pellet " has exactly solved this difficult medical problem, clinical practice proves; This medicine 1 month was 1 course of treatment; Taking after 3 months patients with coronary heart disease can discontinue medication according to practical situation, the healthy in the same old way no any discomfort symptom of health heart, and this medicine has significant curative effect to hypertension, apoplexy sequela, atrial fibrillation, heart failure convalescent care simultaneously.
The specific embodiment
To combine the practical implementation method to specify the present invention below, be used for explaining the present invention in schematic enforcement of the present invention and explanation, but not as to qualification of the present invention.
Embodiment 1:
The invention discloses a kind of specific drug of treating coronary heart disease, comprise the component of following weight portion:
2 parts of Cordyceps, 1.5 parts of Stigma Crocis, 8 parts of Scorpio, 6 parts of Radix Notoginseng, 9 parts of Carapax et Plastrum Testudiniss, 10 parts in Colla Corii Asini, 30 parts of Semen Ziziphi Spinosaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Bulbus Allii Macrostemonis, 3 parts of Herba Asaris, 12 parts of Herba Menthaes, 10 parts of Flos Nelumbinises, 10 parts of the Fructuss Sophorae, 10 parts of vascular aurantii, 24 parts of Herba Cynomoriis.
The medicament mixed of above-mentioned prescription is pulverized together, incapsulate, every 1g, when taking each 4, every day 3 times, one month is a course of treatment.At technical elements, this medicine can adopt the methods such as biological marker, coronarography, zoopery in hemorheology index, the serum that detect, and preparation is carried out the detection of drug effect and toxicity aspect.Clinical proof, general three the course of treatment patient's state of an illness be clearly better, can reduce dose or stop using this moment, the no uncomfortable symptom in back of stopping using.
Embodiment 2:
The invention discloses a kind of specific drug of treating coronary heart disease, comprise the component of following weight portion:
2.1 parts of Cordyceps, 1.6 parts of Stigma Crocis, 8.1 parts of Scorpio, 6.2 parts of Radix Notoginseng, 9.1 parts of Carapax et Plastrum Testudiniss, 10.1 parts in Colla Corii Asini, 30.1 parts of Semen Ziziphi Spinosaes, 10.1 parts of Radix Angelicae Sinensis, 12.1 parts of Bulbus Allii Macrostemonis, 3.2 parts of Herba Asaris, 12.1 parts of Herba Menthaes, 10.2 parts of Flos Nelumbinises, 10.1 parts of the Fructuss Sophorae, 10.1 parts of vascular aurantii, 24.2 parts of Herba Cynomoriis.
The medicament mixed of above-mentioned prescription is pulverized together, incapsulate, every 1g, when taking each 4, every day 3 times, one month is a course of treatment.At technical elements, this medicine can adopt the methods such as biological marker, coronarography, zoopery in hemorheology index, the serum that detect, and preparation is carried out the detection of drug effect and toxicity aspect.Clinical proof, general three the course of treatment patient's state of an illness be clearly better, can reduce dose or stop using this moment, the no uncomfortable symptom in back of stopping using.
Embodiment 3:
The invention discloses a kind of specific drug of treating coronary heart disease, comprise the component of following weight portion:
1.9 parts of Cordyceps, 1.4 parts of Stigma Crocis, 7.9 parts of Scorpio, 5.9 parts of Radix Notoginseng, 8.8 parts of Carapax et Plastrum Testudiniss, 9.9 parts in Colla Corii Asini, 29.8 parts of Semen Ziziphi Spinosaes, 9.8 parts of Radix Angelicae Sinensis, 11.9 parts of Bulbus Allii Macrostemonis, 2.8 parts of Herba Asaris, 11.9 parts of Herba Menthaes, 9.9 parts of Flos Nelumbinises, 9.8 parts of the Fructuss Sophorae, 9.8 parts of vascular aurantii, 23.8 parts of Herba Cynomoriis.
The medicament mixed of above-mentioned prescription is pulverized together, incapsulate, every 1g, when taking each 4, every day 3 times, one month is a course of treatment.At technical elements, this medicine can adopt the methods such as biological marker, coronarography, zoopery in hemorheology index, the serum that detect, and preparation is carried out the detection of drug effect and toxicity aspect.Clinical proof, general three the course of treatment patient's state of an illness be clearly better, can reduce dose or stop using this moment, the no uncomfortable symptom in back of stopping using.
Embodiment 4:
The invention discloses a kind of specific drug of treating coronary heart disease, comprise the component of following weight portion:
2 parts of Cordyceps, 1.5 parts of Stigma Crocis, 8 parts of Scorpio, 6 parts of Radix Notoginseng, 9 parts of Carapax et Plastrum Testudiniss, 10.1 parts in Colla Corii Asini, 30 parts of Semen Ziziphi Spinosaes, 10.1 parts of Radix Angelicae Sinensis, 12.1 parts of Bulbus Allii Macrostemonis, 3.2 parts of Herba Asaris, 12.1 parts of Herba Menthaes, 10.2 parts of Flos Nelumbinises, 10.1 parts of the Fructuss Sophorae, 10.1 parts of vascular aurantii, 24.2 parts of Herba Cynomoriis.
The medicament mixed of above-mentioned prescription is pulverized together, incapsulate, every 1g, when taking each 4, every day 3 times, one month is a course of treatment.At technical elements, this medicine can adopt the methods such as biological marker, coronarography, zoopery in hemorheology index, the serum that detect, and preparation is carried out the detection of drug effect and toxicity aspect.Clinical proof, general three the course of treatment patient's state of an illness be clearly better, can reduce dose or stop using this moment, the no uncomfortable symptom in back of stopping using.
Below be the result of the described clinical drug practical observation of embodiment 1-4, see table one.
Hemorheology index comparison before and after the treatment of table one or two group (x ± s)
Can find out that by last table each item index of blood samples of patients is relatively preceding with treatment
*P＜0.01,
*P＜0.05, with matched group Δ P＜0.01 relatively, explain that the patient takes this medicine after, each index of blood obviously recovery approaches the arm's length standard state, thereby has suppressed the cause of coronary heart disease root.And, there is not significant side effects during the patient takes this medicine and after the drug withdrawal through clinical observation.
The present invention has following beneficial effect:
(1) monarch drug is a Cordyceps in the said preparation, can protect lung kidney tonifying, the logical heart arteries and veins of a surname, relieving cough and resolving phlegm; Ministerial drug is Carapax et Plastrum Testudinis, Colla Corii Asini, Semen Ziziphi Spinosae, but the fire of nourishing YIN for suppressing the hyperactive YANG, moisturizing, tranquilizing by nourishing the heart; Adjuvant drug is Radix Angelicae Sinensis, Radix Notoginseng, Stigma Croci, but nourshing blood and promoting blood circulation blood stasis dispelling, blood vessel dilating, improves blood circulation; Messenger drug is Bulbus Allii Macrostemonis, Herba Asari, but activating stagnated YANG; Herba Menthae can be regulated the flow of vital energy; But Flos Nelumbinis the lucid yang sending up; But Fructus Sophorae removing heat from blood.The monarch medicine complements each other; Adopt the theory of equilibrium between yin and yang, mutual generation of five phases restriction or checking relation in five elements and the integral body sight of the traditional Chinese medical science, dialectical sight; Improve human immunity mechanism through the two accent of QI and blood, blood circulation promoting and blood stasis dispelling, nourishing liver and kidney; The enhances human body resistance, thus reach blood vessel dilating, repair blood vessel wall, increase the effect of heart power, thus really make coronary heart disease heart of patient rehabilitation, healthy.Through clinical verification, after patient used three courses of treatment, cardiac rehabilitation was obvious, and no uncomfortable symptom after the drug withdrawal.
(2) treat the medicine of coronary heart disease on the market now; Usually need the patient to take the development that medicine is controlled coronary heart disease for a long time, and the appearance of " going back heart pellet " has exactly solved this difficult medical problem, clinical practice proves; This medicine 1 month was 1 course of treatment; Taking after 3 months patients with coronary heart disease can discontinue medication according to practical situation, the healthy in the same old way no any discomfort symptom of health heart, and this medicine has significant curative effect to hypertension, apoplexy sequela, atrial fibrillation, heart failure convalescent care simultaneously.
More than the technical scheme that the embodiment of the invention provided has been carried out detailed introduction; Used concrete example among this paper the principle and the embodiment of the embodiment of the invention are set forth, the explanation of above embodiment only is applicable to the principle that helps to understand the embodiment of the invention; Simultaneously, for one of ordinary skill in the art, according to the embodiment of the invention, the part that on the specific embodiment and range of application, all can change, in sum, this description should not be construed as limitation of the present invention.
Claims (3)
1. a specific drug of treating coronary heart disease is characterized in that, comprises the component of following weight portion:
1.8～2.2 parts of Cordyceps, 1.3～1.7 parts of Stigma Crocis, 7.8～8.3 parts of Scorpio, 5.8～6.2 parts of Radix Notoginseng, 8.8～9.2 parts of Carapax et Plastrum Testudiniss, 9.8～10.2 parts in Colla Corii Asini, 29.8～30.3 parts of Semen Ziziphi Spinosaes, 9.7～10.2 parts of Radix Angelicae Sinensis, 11.7～12.3 parts of Bulbus Allii Macrostemonis, 2.8～3.3 parts of Herba Asaris, 11.8～12.3 parts of Herba Menthaes, 9.8～10.3 parts of Flos Nelumbinises, 9.8～10.3 parts of the Fructuss Sophorae, 9.8～10.3 parts of vascular aurantii, 23.8～24.3 parts of Herba Cynomoriis.
2. according to the specific drug of the said treatment coronary heart disease of claim 1, it is characterized in that, comprise the component of following weight portion:
2 parts of Cordyceps, 1.5 parts of Stigma Crocis, 8 parts of Scorpio, 6 parts of Radix Notoginseng, 9 parts of Carapax et Plastrum Testudiniss, 10 parts in Colla Corii Asini, 30 parts of Semen Ziziphi Spinosaes, 10 parts of Radix Angelicae Sinensis, 12 parts of Bulbus Allii Macrostemonis, 3 parts of Herba Asaris, 12 parts of Herba Menthaes, 10 parts of Flos Nelumbinises, 10 parts of the Fructuss Sophorae, 10 parts of vascular aurantii, 24 parts of Herba Cynomoriis.
3. according to the specific drug of the said treatment coronary heart disease of claim 1, it is characterized in that its preparation method is:
Above-mentioned medicaments in part by weight mixed pulverize, quantitatively incapsulate and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100962996A CN102600342B (en) | 2012-04-01 | 2012-04-01 | Specific medicine for treating coronary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100962996A CN102600342B (en) | 2012-04-01 | 2012-04-01 | Specific medicine for treating coronary disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102600342A true CN102600342A (en) | 2012-07-25 |
| CN102600342B CN102600342B (en) | 2013-10-02 |
Family
ID=46518361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100962996A Expired - Fee Related CN102600342B (en) | 2012-04-01 | 2012-04-01 | Specific medicine for treating coronary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102600342B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019974A (en) * | 2007-03-16 | 2007-08-22 | 杨维富 | Chinese medicine capsule for treating coronary heart disease |
| CN101249181A (en) * | 2008-04-09 | 2008-08-27 | 石军 | Removing blood stasisTongmai Chinese medicine compound preparations and method of preparing the same |
| CN101332246A (en) * | 2008-08-02 | 2008-12-31 | 蔡青 | Traditional Chinese medicine preparation for treating coronary heart disease and angina |
-
2012
- 2012-04-01 CN CN2012100962996A patent/CN102600342B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019974A (en) * | 2007-03-16 | 2007-08-22 | 杨维富 | Chinese medicine capsule for treating coronary heart disease |
| CN101249181A (en) * | 2008-04-09 | 2008-08-27 | 石军 | Removing blood stasisTongmai Chinese medicine compound preparations and method of preparing the same |
| CN101332246A (en) * | 2008-08-02 | 2008-12-31 | 蔡青 | Traditional Chinese medicine preparation for treating coronary heart disease and angina |
Non-Patent Citations (2)
| Title |
|---|
| 王永安: "《中医治疗冠心病》", 30 April 1995, 山东科学技术出版社 * |
| 苏士印: "冠心病中药处方方法探讨", 《辽宁中医药大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102600342B (en) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078510B (en) | Chinese medicinal composition for treating coronary heart disease | |
| CN101507765B (en) | Medicine for treating cerebrovascular disease and sequela thereof and preparation method thereof | |
| CN102614391A (en) | Traditional Chinese medicine for treating cerebrovascular disease and preparation method thereof | |
| CN100333750C (en) | Chinese medicinal preparation for treating qi obstruction in chest and heart palpitation and its preparation process | |
| CN104758353A (en) | Medicine composition for treating cardiovascular diseases, preparation method and application thereof | |
| CN101721608B (en) | Chinese herbal medicine pill used for treating heart diseases | |
| CN101780140B (en) | Drug for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102872455B (en) | Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method | |
| CN102600342B (en) | Specific medicine for treating coronary disease | |
| CN103690643B (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN103908490A (en) | Pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and preparation method thereof | |
| CN100536890C (en) | Traditional Chinese medicine composition for preventing arrhythmia and processes for producing same | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN101716236A (en) | Chinese medicinal composition for adjunctively treating left ventricular insufficiency after acute myocardial infarction and preparation method thereof | |
| CN101856480B (en) | Chinese medicament for treating myocardial infarction | |
| CN101884708B (en) | Chinese medicinal menstruation conditioning decoction for treating preceded menstural cycle | |
| CN103301299A (en) | Chinese medicine composition for improving cardiac function after myocardial infarction | |
| CN102600255A (en) | Coronary disease treatment capsule | |
| CN102716293A (en) | Capsule for treating hypertension, hyperlipemia, arteriosclerosis and coronary heart disease | |
| CN102764381A (en) | Traditional Chinese medicine composite for curing cerebral infarction sequelae | |
| CN102406843A (en) | Chinese medicinal composition for treating coronary disease | |
| CN101869689B (en) | External Chinese medicinal composition for treating angina pectoris coronary heart disease | |
| CN105055810B (en) | A kind of composition and preparation method thereof for capableing of increasing high density lipoprotein | |
| CN105343358A (en) | Traditional Chinese medicine capsules for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131002 Termination date: 20190401 |